New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline

NEW YORK, September 16, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Allergan Inc. (NYSE: AGN), Mylan, Inc. (NASDAQ: MYL), AstraZeneca PLC (NYSE: AZN), and GlaxoSmithKline plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Merck & Co. Inc. Research Report

On September 9, 2013, Merck & Co. Inc. (Merck) announced that its New Drug Application (NDA) for the investigational fertility treatment, corifollitropin alfa, has received acceptance for standard review by the US Food and Drug Administration (FDA). Further, Merck stated that it is seeking FDA approval of corifollitropin alfa for Controlled Ovarian Stimulation (COS) in women participating in assisted reproductive technology, which if approved, will mark corifollitropin alfa as the first sustained follicular stimulant for use in a fertility treatment regimen. Barbara Stegmann, M.D., Reproductive Endocrinology and Infertility Specialist, and Principal Scientist and Clinical Lead Fertility, Merck, said, "The filing of corifollitropin alfa is an example of Merck's commitment to patients and scientific innovation." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-11/MRK]

--

Allergan Inc. Research Report

On September 11, 2013, Allergan Inc. (Allergan) announced that the US Food and drug Administration (FDA) has approved the marketing of its BOTOX Cosmetic (onabotulinumtoxinA), for an additional indication to temporarily treat moderate to severe lateral canthal lines, commonly known as "crow's feet" lines. Scott W. Whitcup M.D., Executive Vice President, Research and Development, Chief Scientific Officer at Allergan, said,  "We are pleased that the FDA has approved a new indication for BOTOX Cosmetic to temporarily improve the appearance of crow's feet lines. With this approval, BOTOX Cosmetic is now the only pharmaceutical approved to treat both crow's feet lines and frown lines between brows. This approval will enhance our ability to work with and train aesthetic physicians on the science of administering BOTOX Cosmetic to yield the best possible outcomes for patients." The Full Research Report on Allergan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-11/AGN]

--

Mylan, Inc. Research Report

On September 3, 2013, Mylan Inc. (Mylan) announced that India's Foreign Investment Promotion Board (FIPB) and Cabinet Committee on Economic Affairs (CCEA) have approved its proposed acquisition of the Agila injectables businesses from Strides Arcolab Limited. Mylan's CEO, Heather Bresch commented, "We are very pleased to have received all outstanding Indian pre-merger regulatory approvals for the Agila transaction, especially considering the increased government regulation and oversight with respect to foreign investment in India. We look forward to completing the acquisition in the coming months, which we believe will establish Mylan as a global injectables leader, with a significantly expanded and strengthened injectables portfolio, pipeline, platform and capabilities." The Company expects the transaction to close in Q4 2013, subject to remaining regulatory approvals and certain closing conditions. The Full Research Report on Mylan, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-11/MYL]

--

AstraZeneca PLC Research Report

On September 11, 2013, AstraZeneca PLC (AstraZeneca) announced that it has entered into a worldwide licensing agreement with Merck Co. Inc. (Merck) for the latter's oral small molecule inhibitor of WEE1 kinase (MK-1775). The Company informed that MK-1775 is undergoing evaluation in Phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer. Under the terms of agreement, AstraZeneca will pay $50 million upfront fee and will be responsible for all future clinical development, manufacturing and marketing, while Merck will be eligible to receive future payments tied to development and regulatory milestones plus sales-related payments and tiered royalties. "MK-1775 is a strong addition to AstraZeneca's growing oncology pipeline, which already includes a number of inhibitors of the DNA damage response," said Susan Galbraith, Head of AstraZeneca's Oncology Innovative Medicines Unit. "The compound has demonstrated encouraging clinical efficacy data and we intend to study it in a range of cancer types where there is a high unmet medical need." The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-11/AZN]

--

GlaxoSmithKline plc Research Report  

On September 9, 2013, GlaxoSmithKline plc (GSK) announced that it has signed an agreement to sell its nutritional drink brands, Lucozade and Ribena, to Suntory Beverage & Food Ltd. (SBF) against a consideration of c.£1.4 billion in cash. The Company informed that under the terms of the agreement, SBF will acquire global rights to the brands and GSK's Coleford manufacturing site, located in the Forest of Dean in the UK, however, in Nigeria, GSK will continue to manufacture and distribute Lucozade and Ribena under licence from SBF. David Redfern, Chief Strategy Officer, GSK, said, "Lucozade and Ribena are iconic brands that have made a huge contribution to GSK over the years, but now is the right time to sell them as we increase the focus of our Consumer Healthcare business and execute the delivery of our late stage pipeline of pharmaceuticals and vaccines." The Company expects the transaction to be completed by the end of 2013, subject to regulatory approvals. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-11/GSK]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports